Abstract
To establish stable hybrid cell lines producing human anti-tetanus antibody with high toxinneutralizing activity, peripheral lymphocytes from humans hyperimmunized with tetanus toxoid were, after in vitro antigen stimulation, fused with a mouse/human heteromyeloma or human lymphoblastoid cell line and cloned. Unlike the IgM secretors (six clones), the IgG secretors we obtained (six clones) produced anti-tetanus human monoclonal antibodies with high neutralizing activity (the highest one, cell line G2, 4.3 IU/100 μg IgG).
Appropriate combinations of three or four kinds of monoclonal antibodies of the IgG type resulted in markedly increased neutralizing activity comparable with that of anti-tetanus human polyclonal immunoglobulin preparations currently used clinically on the basis of toxin-specific IgG content. Five of these cell lines produced 10≈20 pg of antibody per ml for more than 3 months. The cell line G2 produced 6 mg of antibody per day in serum-free medium in a 500-ml bioreactor in perfusion culture and 13–104 mg in a nude mouse. These cell lines satisfied, for the first time, the minimal requirements for applying human monoclonal antibodies to clinical use.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
AleshkinV.A., BorisovaV.N., PonomaryovaA.M. and PopkovM.Y.U. (1989): Production of homologous tetanus antitoxin from commercial γ-globulin preparations. - In: Proceedings of the 8th International Conference on Tetanus. G. Nisticò, B. Bizzini, B. Bytchenko and R. Triau (eds.) - Pythagora Press, Rome-Milan, pp. 285–290.
BoydJ.E., HastingsI., FarzadZ., JamesK. and McClellandD.B.L. (1984):Experiences in the production of human monoclonal antibodies to tetanus toxoid. - Develop. Biol. Standard. 57: 93–98.
EbisawaI., MatsuhashiC., YamamotoA., KurosuY. and OtsukaT. (1981): Clinical experiences in the use of intravenously injectable tetanus-immune human gamma globulin in TIG(i). - Kansenshogaku Zasshi (J Jpn Assoc Infect Dis) 55: 92–98 (in Japanese).
GigliottiF. and InselR.A. (1982): Protective human hybridoma antibody to tetanus toxin. - J. Clin. Invest. 70: 1306–1309.
GigliottiF., SmithL. and InselR.A. (1984): Reproducible production of protective human monoclonal antibodes by fusion of peripheral blood lymphocytes with a mouse myeloma cell line. - J. Infect. Dis. 149: 43–47.
HashizumeS., MochizukiK., MurakamiH., YanoT., YasumotoK. and NomotoK. (1989): Serodiagnosis of cancer, using porcine antigens recognized by human monoclonal antibody, HB4C5. - Biotherapy 1: 109–115.
HirataY. and SugawaraI. (1987): Characterization of mouse-human hybridoma as a useful fusion partner for the establishment of mouse-human-human hybridoma secreting anti-tetanus toxoid human monoclonal antibody of IgM or IgG class. -Microbiol. Immunol. 31: 231–245.
IchimoriY., SasanoK., ItohH., HitotsumachiS., KimuraY., KanekoK., KidaM. and TsukamotoK. (1985): Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. - Biochem. Biophys. Res. Commun. 129: 26–33.
KozborD. and RoderJ.C. (1981): Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein Barr virus technique. - J. Immunol. 127: 1275–1280.
KozborD. and RoderJ.C. (1983): The production of monoclonal antibodies from human lymphocytes. -Immunol. Today 4: 72–79.
KozborD., RoderJ.C., ChangT.H., SteplewskiZ. and KoprowskiH. (1982): Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. -Hybridoma 1: 323–328.
LaemmliU.K. (1979): Cleavage of structural proteins during the assembly of the head of bacteriophage T4.- Nature 227: 680–685.
LarrickJ.W., TruittK.E., RaubitschekA.A., SenykG. and WangJ.C.N. (1983): Characterization of human hybridomas secreting antibody to tetanus toxoid. -Proc. Nall. Acad. Sci. USA 80: 6376–6380.
MatsudaM. (1989): The structure of tetanus toxin. -In: Botulinum Neurotoxin and Tetanus Toxin. L. Simpson (ed.). - Academic Press., Inc. New York pp. 69–92.
MatsudaM., SugimotoN. and OzutsumiK. (1982): Acute botulinum-like intoxication by tetanus toxin in mice and the localization of the acute toxicity in the N-terminal papain-fragment of the toxin. - In: Proceedings of the 6th International Conference on Tetanus. Fondation Marcel Mérieux, Lyon, pp. 21–32.
MatsudaM. and YonedaM. (1975): Isolation and purification of two antigenically active, “complementary” polypeptide fragments of tetanus neurotoxin. - Infect. Immun. 12: 1147–1153.
MatsudaM. and YonedaM. (1977): Antigenic substructure of tetanus neurotoxin. - Biochem. Biophys. Res. Commun. 77: 268–274.
MillerR.A., MaloneyD.G., WarnkeR. and LevyR. (1982): Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. - New England J. Med. 306: 517–522.
MiyazakiY. (1983): Establishment of human monoclonal antibody reactive with B lymphoblastoid cell lines and Burkitt's lymphoma. - In: Jpn. Soc. Immunol. Experimental Procedures in Immunology (ed.), Vol. 12. Jpn. Soc. Immunol., Kanazawa, pp. 3975–3979 (in Japanese).
MizuguchiJ., YoshidaR., SatoY., NagaokaF., KondoS. and MatuhasiT. (1982): Requirements for at least two distinct monoclonal antibodies for efficient neutralization of tetanus toxin in vivo. -Naturwissenschaften 69: 597–598.
MurakamiH., HashizumeS., OhashiH., ShinoharaK., YasumotoK., NomotoK. and OmuraH. (1985): Human-human hybridomas secreting antibodies specific to human lung carcinoma. - In vitro Cell. Develop. Biol. 21: 593–596.
OakleyB.R., KirschD.R. and MorrisN.R. (1980): A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels. - Anal. Biochem. 105: 361–363.
OhashiH., HashizumeS., MurakamiH., AiharaK., ShinoharaK. and OmuraH. (1986): HO-323, a human B-lymphoblastoid cell line useful for making human-human hybridomas. - Cell Biol. Intern. Rep. 10: 77–83.
OzutsumiK., LeiD.L., SugimotoN. and MatsudaM. (1989): Isolation and purification by high performance liquid chromatography of a tetanus toxin fragment (Fragment [A-B]) derived from mildly papain-treated toxin. - Toxicon 27: 1055–1057.
PattY.Z., LamkiL.M., HaynieT.P., UngerM.W., RosenblumM.G., ShirkhodaA. and MurrayJ.L. (1988): Improved tumour localization with increasing dose of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 in metastatic colorectal cancer. - J. Clin. Oncol. 6: 1220–1230.
PosnerM.R., ElboimH. and SantosD. (1987): The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies.- Hybridoma 6: 611–625.
SaxonA., FeldhausJ. and RobinsR.A. (1976): Single step separation of human T and B cells using AET treated SRBC rosettes. - J. Immunol. Methods 12: 285–288.
SearsH.F., AtkinsonB., MattisJ., ErnstC., HerlynD., SteplewskiZ., HäyryP. and KoprowskiH. (1982): Phase I clinical trial of monoclonal antibody in treatment of gastrointestinal tumour. - Lancet 1: 762–765.
TengN.N.H., LamK.S., RieraF.C. and KaplanH.S. (1983): Construction and testing of mouse-human heteromyelomas for human monoclonal antibody production. - Proc. Natl. Acad. Sci. USA 80: 7308–7312.
Tiebout, R.F., StrickerE.A.M., HagenaarsR. and ZeijlemakerW.P. (1984): Human lymphoblastoid cell line producing protective monoclonal IgG1, kappa anti-tetanus toxin. - Eur. J. Immunol. 14: 399–404.
VolkW.A., BizziniB., SnyderM., BernhardE. and WagnerR.R. (1984): Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. - Infect. Immun. 45: 604–609.
Ziegler-HeitbrockH.W.L., ReiterC., TrenkmannJ., FuttererA. and RiethmullerG. (1986): Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule. - Hybridoma 5: 21–31.
ZurawskiV.R. Jr., HAberE. and BlackP.H. (1978): Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines. -Science 199: 1439–1441.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kamei, M., Hashizume, S., Sugimoto, N. et al. Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity. Eur J Epidemiol 6, 386–397 (1990). https://doi.org/10.1007/BF00151713
Issue Date:
DOI: https://doi.org/10.1007/BF00151713